Hospital
Prime Healthcare Services - Shasta LLC
Prime Healthcare Services - Shasta LLC was paid $22.75M by Medicaid between Jan 2018 and Nov 2024, across 181 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 24% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - SHASTA LLC
REDDING, CA 96001
REDDING, CA 96001
33aNPI1205089026assigned 10/23/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.75M
24GClaims538,027
24DCodes billed181
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#113 of 410
Median peer was paid$6.90M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,884 | $3.51M | |
| 2019 | 91,084 | $3.17M | |
| 2020 | 79,927 | $2.77M | |
| 2021 | 75,049 | $3.50M | |
| 2022 | 71,844 | $3.43M | |
| 2023 | 80,099 | $3.97M | |
| 2024incomplete | 49,140 | $2.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 24% | 41,130 | 35,891 | $5.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 71,676 | 59,286 | $4.25M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.1% | 8,909 | 8,201 | $926K |
| 99070 | 3.5% | 29,091 | 20,328 | $792K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.5% | 3,418 | 2,002 | $789K |
| J3490 | Unclassified drugs | 3.4% | 49,222 | 28,501 | $764K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 14,056 | 12,620 | $714K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.0% | 7,964 | 7,072 | $689K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 2,889 | 2,821 | $646K |
| 99201 | 2.7% | 4,177 | 2,903 | $612K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.7% | 11,558 | 10,734 | $611K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 2,678 | 2,640 | $540K |
169 more codes
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.3% | 3,943 | $520K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 1,110 | $455K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,940 | $397K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 5,580 | $281K |
| 80053 | Comprehensive metabolic panel | 1.0% | 28,590 | $233K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,751 | $223K |
| 97597 | <1% | 2,705 | $182K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,876 | $182K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,328 | $166K |
| 93976 | <1% | 367 | $162K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,991 | $151K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,204 | $144K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 351 | $126K |
| 0450 | Emergency room services | <1% | 2,706 | $122K |
| 83880 | <1% | 4,376 | $110K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,324 | $106K |
| 90715 | <1% | 2,039 | $105K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,122 | $82K |
| Z7502 | <1% | 2,143 | $82K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 648 | $77K |
| 80305 | <1% | 6,439 | $76K | |
| 84484 | <1% | 7,250 | $76K | |
| 73610 | <1% | 1,561 | $72K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,724 | $71K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,907 | $68K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,276 | $66K |
| 73130 | <1% | 1,441 | $65K | |
| 84145 | <1% | 2,665 | $60K | |
| 73630 | <1% | 1,408 | $58K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,363 | $54K |
| 73110 | <1% | 1,187 | $53K | |
| 73564 | <1% | 1,003 | $50K | |
| 81001 | <1% | 13,655 | $50K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,031 | $49K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 611 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,814 | $46K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,488 | $45K |
| 83690 | <1% | 8,570 | $44K | |
| 10060 | <1% | 1,080 | $44K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 28 | $43K |
| 93971 | <1% | 216 | $42K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 447 | $36K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,888 | $34K |
| 81025 | <1% | 9,113 | $32K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 69 | $32K |
| 73030 | <1% | 690 | $31K | |
| 87503 | <1% | 1,324 | $30K | |
| 87040 | <1% | 2,410 | $30K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,584 | $29K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,628 | $28K |
| 83605 | <1% | 2,827 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 234 | $25K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,137 | $24K |
| 87088 | <1% | 4,267 | $24K | |
| 97598 | <1% | 84 | $24K | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 319 | $22K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,339 | $21K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,748 | $21K |
| 87186 | <1% | 2,635 | $21K | |
| 85610 | <1% | 6,069 | $21K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,036 | $20K |
| 87077 | <1% | 2,767 | $19K | |
| 83735 | <1% | 3,532 | $18K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,462 | $18K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,536 | $18K |
| 85730 | <1% | 3,384 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 32 | $17K |
| 29125 | <1% | 1,172 | $17K | |
| 82948 | <1% | 5,244 | $16K | |
| 12001 | <1% | 438 | $16K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,502 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 566 | $12K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 539 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,739 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,894 | $12K |
| 81003 | <1% | 4,841 | $10K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 67 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 561 | $9K |
| 49083 | <1% | 110 | $8K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 459 | $8K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 484 | $8K |
| 73080 | <1% | 181 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,190 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 61 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 948 | $7K |
| 85379 | <1% | 962 | $7K | |
| 87070 | <1% | 972 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 825 | $7K |
| 87081 | <1% | 1,189 | $6K | |
| 73221 | <1% | 38 | $5K | |
| 99199 | Unlisted special service, procedure or report | <1% | 110 | $5K |
| 95816 | <1% | 65 | $5K | |
| 12002 | <1% | 119 | $4K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 217 | $4K |
| 73090 | <1% | 84 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 321 | $4K |
| A6206 | Contact layer, sterile, 16 sq. in. or less, each dressing | <1% | 188 | $4K |
| 73140 | <1% | 138 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 109 | $4K |
| 94060 | <1% | 31 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $4K |
| Z7610 | <1% | 252 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 328 | $3K |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 12 | $3K |
| 70486 | <1% | 12 | $3K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 186 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 36 | $3K |
| 74018 | <1% | 81 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 27 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 161 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 253 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 221 | $2K |
| 82150 | <1% | 375 | $2K | |
| 86885 | <1% | 452 | $2K | |
| 29515 | <1% | 128 | $2K | |
| 0250 | <1% | 230 | $2K | |
| 72100 | <1% | 60 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 86901 | <1% | 696 | $1K | |
| 86900 | <1% | 695 | $1K | |
| 86140 | <1% | 398 | $1K | |
| 96368 | <1% | 27 | $1K | |
| 85007 | <1% | 556 | $1K | |
| 71271 | <1% | 12 | $1K | |
| A6255 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 148 | $1K |
| 12011 | <1% | 25 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,841 | $1K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 61 | $1K |
| A7000 | Canister, disposable, used with suction pump, each | <1% | 266 | $1K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 78 | $955.58 |
| 72110 | <1% | 32 | $938.06 | |
| 0270 | <1% | 112 | $739.64 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 156 | $734.98 |
| 87075 | <1% | 87 | $682.37 | |
| 94760 | <1% | 38 | $679.76 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 15 | $628.65 |
| 76775 | <1% | 27 | $626.29 | |
| 76536 | <1% | 12 | $552.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 77 | $471.20 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 89 | $411.19 |
| 29505 | <1% | 28 | $383.40 | |
| 85651 | <1% | 186 | $348.95 | |
| 80076 | <1% | 62 | $317.50 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 13 | $301.56 |
| 72040 | <1% | 18 | $295.97 | |
| 0637 | <1% | 32 | $295.48 | |
| J1815 | Injection, insulin, per 5 units | <1% | 32 | $272.64 |
| 84439 | <1% | 42 | $267.44 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 42 | $263.01 |
| 11043 | <1% | 18 | $255.60 | |
| 85008 | <1% | 488 | $251.29 | |
| 73502 | <1% | 12 | $248.31 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 57 | $240.84 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 607 | $235.78 |
| A6266 | Gauze, impregnated, other than water, normal saline, or zinc paste, sterile, any width, per linear yard | <1% | 49 | $221.07 |
| 82550 | <1% | 43 | $204.62 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 12 | $192.00 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 19 | $181.39 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 28 | $172.61 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 106 | $166.72 |
| 87210 | <1% | 12 | $121.44 | |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 12 | $119.39 |
| 87102 | <1% | 14 | $101.15 | |
| 84100 | <1% | 29 | $88.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,328 | $79.29 |
| 80178 | <1% | 13 | $57.12 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 562 | $30.33 |
| 36415 | Collection of venous blood by venipuncture | <1% | 294 | $26.24 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 78 | $11.25 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (CHIEF COMPLIANCE COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.